Advanced Biomed (ADVB) stock price is $3.80, down 8.65% on the day, as of Oct 20, 2026. It has a market cap of $4.88Mn, and is classified in the Diagnostic Equipment industry (Healthcare sector).
Enterprise Value
Margins
P/FCF
Key Stats
Market Cap4.88 Mn
P/E0.92
P/S-59,974.70
Div. Yield0.00
Add ratio to table…
About
Advanced Biomed Inc is a holding company incorporated in the State of Nevada that operates through subsidiaries in Taiwan and Hong Kong, focusing on the integration of semiconductor technology and biotechnology to develop microfluidic technology platforms for cancer detection.
The company generates revenue through the development and planned commercialization of medical testing equipment and related products, including microfluidic biochips, immunostaining kits, and devices…
Advanced Biomed Inc is a holding company incorporated in the State of Nevada that operates through subsidiaries in Taiwan and Hong Kong, focusing on the integration of semiconductor technology and biotechnology to develop microfluidic technology platforms for cancer detection.
The company generates revenue through the development and planned commercialization of medical testing equipment and related products, including microfluidic biochips, immunostaining kits, and devices such as A+Pre, AC-1000, A+CellScan, A+SCDrop, and A+LCGuard, targeting healthcare providers and research institutions for cancer screening and diagnosis.
The company operates through the following segments: Advanced Biomed Taiwan and Advanced Biomed HK.
Advanced Biomed Taiwan is responsible for the main operation and the design and development of the company’s primary technologies and products.
Advanced Biomed HK is mainly responsible for market operation and management in China, localized production, product registration, and future local market sales of the company’s products in accordance with relevant local regulations in China.
Advanced Biomed Inc positions itself as an innovator in the oncology detection market by leveraging its proprietary microfluidic technology platform and antigen-independent rare cell enrichment system, which offers advantages over conventional antibody-based methods in terms of cost, processing time, and ability to detect circulating tumor cells with low antigen expression.
The company serves hospitals, clinical laboratories, and research institutions, particularly in China, with plans to expand to North American and European markets through localized subsidiaries to meet regional regulatory requirements.
Sector:HealthcareSector rationaleThe company develops and sells medical testing equipment and products, such as microfluidic biochips and immunostaining kits, specifically for cancer screening and diagnosis. Its primary customers are hospitals, clinical laboratories, and research institutions, which aligns directly with the Medical Devices and Diagnostic Equipment industries within the Healthcare sector.Industries:Diagnostic EquipmentDiagnostic EquipmentPrimaryAdvanced Biomed develops and sells medical testing equipment for cancer screening and diagnosis, specifically microfluidic biochips and devices like A+Pre and AC-1000. These products are sold to hospitals and clinical laboratories as diagnostic platforms and assays.Life Sciences ToolsLife Sciences ToolsSecondaryThe company targets research institutions with its microfluidic technology platforms and related products for oncology detection.Classified using BQ-MICSCIK: 0001941029
Peer percentiles
How Advanced Biomed ranks
Ranked against the 248 companies in Medical Devices and Diagnostics·58 metrics · as of Oct 16, 2026
Valuation
12 metrics · Lower multiples rank higher; a negative multiple ranks last